From Imperfective to Progressive via Relative Present

Proceedings of the Twenty-Sixth Annual Meeting of the Berkeley Linguistics Society: General Session and Parasession on Aspect (2000

«MEDITERRANEAN CARD» IN ITALY’S EUROPEAN POLICY

It has always been important for Italian foreign policy to have a political weight both in the EU and in the Mediterranean. The country is trying to play on several boards, building different configurations, and does not limit itself solely to the ideas of the Rome – Paris – Berlin triangle. Realizing their vulnerability and the danger of being in a subordinate position among France and Germany, Italy is relying on the «Mediterranean card», building an informal union of the countries of Southern Europe (Italy, Spain, Greece, Cyprus, Malta, Portugal). With G. Meloni becoming primeminister, the Mediterranean continues to be in the rank of priority areas of Italy’s foreign policy. Playing the «Mediterranean card» is now easier because countries are creating the image of a common enemy for Europe. Despite attempts to consolidate informal cooperation between the countries of Southern Europe around the Mediterranean, it is not quite successful due to the economic weakness of the countries and the lack of proper political authority. However, there is tactical cooperation in the context of inter-Mediterranean energy cooperation, where Italy is achieving a coordinating role. After the British withdrawal from the EU, Rome is keen to take over the British seat, which could also strengthen the country’s role in the Mediterranean. The main competitor, jealous of Italy’s claim to leadership in both the EU and the Mediterranean, is France; the sub-regional competitor in the Mediterranean is Spain, which does not currently have enough resources to pursue its political ambitions

SOFOSBUVIR: TREATMENT OF CHRONIC HEPATITIS C AND THE MAIN TRENDS IN PATENT PROTECTION

The purpose of the study was to analyze and systematize the literature data on the benefit/risk ratio of sofosbuvir administration in the treatment of patients with chronic hepatitis C and the main trends in its patent protection. Studies were conducted using databases on the Internet: Ukrainian patent office, the European patent office, the US patent office, the Food and drug administration, European Medicines Agency (EMEA), State enterprise “The State Expert Center” of the Ministry of Health of Ukraine. It has used retrospective, logical, systematic and analytical methods. Data from clinical studies abroad and meta-analyses indicate that sofosbuvir is one of the most promising drugs for the treatment of chronic HCV infection. Its indisputable advantages are that this drug can be used with different genotypes of the virus, decompensated liver function, it is well tolerated. Sofosbuvir has an improved safety profile and a low probability of viral resistance. The high cost of sofosbuvir is due to the powerful patent protection. As mechanisms for working with patent barriers, it is recommended to use the flexible mechanisms of the TRIPS Agreement: the grant of compulsory licenses, the implementation of parallel imports, the tightening of the criteria for patentability (prohibition of patenting new forms that do not improve therapeutic efficacy)

The Export Industrial Subsidies in the Regions of the Russian Federation: their Characteristic and WTO Compliance

Export of hi-tech and some other large enterprises, and also small and medium-sized enterprises is supported at the regional level in the Russian Federation. As regards to small and medium sized enterprises co-financing from the federal budget makes 50-80%. There is a standard tool kit of export help for SME which can be expanded at subnational level. Export support program of the Leningrad and Rostovregionas well as programs for SME havea form of export subsidy from WTO point of view

Value formation of innovative product : a way to commercialization

Purpose: The issues of studying the value formation process of an innovative product, from the idea to the prototype to the commercialization of the output from the production line, depending on the type of innovations, are the aims of this article. Design/Methodology/Approach: The conceptual framework of "value" and "innovations" is explored and the theoretical basis of the value approach is revealed at the beginning of the article. The definition of an innovative product is given and the development process and the mechanism of its value formation at each development phase are revealed. Findings: The value-added elements are specified, from the idea generation to the commercialization of the innovative product. The expenses for the calculation items and the development phases of the innovative product are estimated. Practical Implications: Categories of the innovation-based economy development, as "innovation", "innovative product", and "value" are not sufficiently studied. Intensive discussions are taking place in the scientific community regarding what an innovative product is and how its value is formed. A specific result of intellectual activity, at the initial stage of its formation represents an idea that is difficult to be estimated. Originality/Value: The problematics for further research of value formation of innovative products depending on their specific nature is put.The article was prepared in the course of carrying out research work within the framework of the project part of the state task in the field of scientific activity in accordance with the task No. 26.2758.2017 / PCh (26.2758.2017 / 4.6) for 2017-2019 on the topic "System for the formation and distribution analysis of the value of innovative products based on the infrastructure concept".peer-reviewe

Association of Bone Loss with the Upregulation of Survival-Related Genes and Concomitant Downregulation of Mammalian Target of Rapamycin and Osteoblast Differentiation-Related Genes in the Peripheral Blood of Late Postmenopausal Osteoporotic Women

We aimed to identify bone related markers in the peripheral blood of osteoporotic (OP) patients that pointed toward molecular mechanisms underlying late postmenopausal bone loss. Whole blood from 22 late postmenopausal OP patients and 26 healthy subjects was examined. Bone mineral density (BMD) was measured by DXA. Protein levels of p70-S6K, p21, MMP-9, TGFβ1, and caspase-3 were quantified by ELISA. Gene expression was measured using real-time RT-PCR. OP registered by low BMD indices in late postmenopausal patients was associated with a significant upregulation of autophagy protein ULK1, cyclin-dependent kinase inhibitor p21, and metalloproteinase MMP-9 gene expression in the blood compared to the healthy controls and in a significant downregulation of mTOR (mammalian target of rapamycin), RUNX2, and ALPL gene expression, while expression of cathepsin K, caspase-3, transforming growth factor (TGF)β1, interleukin- (IL-) 1β, and tumor necrosis factor α (TNFα) was not significantly affected. We also observed a positive correlation between TGFβ1 and RUNX2 expression and BMD at femoral sites in these patients. Therefore, bone loss in late postmenopausal OP patients is associated with a significant upregulation of survival-related genes (ULK1 and p21) and MMP-9, as well as the downregulation of mTOR and osteoblast differentiation-related genes (RUNX2 and ALPL) in the peripheral blood compared to the healthy controls